Welcome to our dedicated page for Privia Health Group SEC filings (Ticker: PRVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Privia Health Group, Inc. files SEC reports that document its physician enablement business, operating results, governance and public-company capital structure. Its 8-K reports commonly furnish quarterly and annual financial releases, including revenue, care margin, platform contribution, adjusted EBITDA, guidance, value-based risk arrangements and provider-network growth.
Proxy and other material-event filings cover board and committee governance, shareholder voting matters, material agreements, risk factors, regulatory disclosures and other updates tied to a Delaware corporation listed on Nasdaq under PRVA.
PRVA reported proposed insider sales via a Form 144 notice. The filing lists multiple planned cash sales of Common shares, with option-derived share amounts shown for grants dated 08/28/2018, 03/20/2019, 12/04/2019, and 09/08/2020. The filing also lists actual open-market dispositions by a reported holder on specific dates in 2026.
PRVA reported insider sell transactions via Form 144 for Common stock. The filing lists multiple open-market sales by David Mountcastle with individual trades such as 5,361 shares for $134,030.87 on 02/26/2026 and 7,697 shares for $192,798.08 on 02/27/2026. The record also shows option-related securities listed with grant dates and exercise/Cash treatment.
PRVA insider registered proposed sales of common stock. The filing lists two recent dispositions: 7,788 shares on 02/26/2026 and 16,550 shares on 02/27/2026 (the latter reported with $413,745.04 proceeds). The notice also lists larger holdings tied to Restricted Stock Units dated 08/28/2018.
Vanguard Portfolio Management filed a Schedule 13G reporting beneficial ownership of 6,382,685 shares of Privia Health Group Inc. The filing shows this position represents 5.16% of the class and reports 101,143 shares of sole voting power and 6,382,685 shares of sole dispositive power as of 03/31/2026.
The disclosure includes Vanguard's customary explanatory statement: the holdings reflect securities over which Vanguard Portfolio Management LLC and certain affiliates exercise dispositive power, including shares held by Vanguard funds and managed accounts.
Privia Health Group EVP & CFO David Mountcastle reported an open-market sale of 5,566 shares of common stock at $20.85 per share on April 2, 2026. According to the footnote, this was a nondiscretionary “sell to cover” transaction to satisfy tax withholding obligations from vesting restricted stock units.
After the sale, Mountcastle directly holds 214,847 shares of Privia Health Group common stock and has an additional 8,695 shares held indirectly through his spouse.
David Mountcastle filed a Form 144 reporting proposed sales of Common Stock of PRVA. The filing lists multiple sale entries tied to open-market dispositions and a separate restricted stock vesting on 04/01/2026.
Reported sale examples include 5,361 shares on 02/26/2026 for $134,030.87 and 7,697 shares on 02/27/2026 for $192,798.08, with additional sales in March 2026.
Privia Health Group, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on May 20, 2026 at 11:00 a.m. Eastern Time. Proposals include electing three Class I directors to terms ending in 2029, an advisory “say‑on‑pay” vote on named executive officer compensation, and ratifying PricewaterhouseCoopers LLP as independent auditor for 2026.
The Board remains classified into three staggered classes and currently has nine directors, most of whom are independent and serve on key committees covering audit, compensation, nominating and governance, and compliance. The company highlights stockholder outreach, strong governance policies such as anti‑hedging and anti‑pledging rules, a robust insider trading policy, and broad ESG, cybersecurity, and talent management initiatives.
Privia Health Group Inc: The Vanguard Group filed a Schedule 13G/A amendment reporting 0 shares and 0% beneficial ownership of Privia Health common stock. The filing explains an internal realignment on January 12, 2026 that led to disaggregated reporting by Vanguard subsidiaries. The form lists Vanguard's business address and is signed on 03/27/2026 by Ashley Grim, Head of Global Fund Administration.
Privia Health Group EVP & Chief Financial Officer David Mountcastle reported an open-market sale of 6,391 shares of common stock at $22.11 per share. According to the footnote, this was a nondiscretionary sale-to-cover transaction required to satisfy tax withholding obligations tied to vesting performance stock units.
After the sale, he held 220,413 shares directly and 8,695 shares indirectly through his spouse, indicating that the sale represents a small portion of his overall ownership and is linked to equity compensation tax requirements rather than a discretionary portfolio move.